Jemperli (dostarlimab) plus chemotherapy application accepted for review by the European Medicines Agency to expand use to all patients with primary advanced or recurrent endometrial cancer

Jemperli (dostarlimab) plus chemotherapy application accepted for [...]

2024-07-01T13:26:47+01:00News|

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc [...]

2024-06-14T15:16:35+01:00News|
Go to Top